AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
PolyPid to Present at Israel Controlled Release Society Conference: Insights into PLEX Technology
ByAinvest
Wednesday, Sep 3, 2025 1:22 am ET1min read
PolyPid Ltd. (PYPD) will present at the 14th Israel Controlled Release Society Conference. Deputy CEO Dalit Hazan will present "Novel Local Prolonged Drug Delivery: From Platform Idea to a Successful Phase III Trial." The company specializes in advanced drug delivery systems to improve surgical outcomes. PolyPid plans to submit an NDA for its lead product candidate, D-PLEX, by early 2026.
PolyPid Ltd. (PYPD), a late-stage biopharmaceutical company focused on enhancing surgical outcomes, has announced that Deputy CEO Dalit Hazan will present at the 14th Israel Controlled Release Society (ICRS) Conference. The presentation, titled "Novel Local Prolonged Drug Delivery: From Platform Idea to a Successful Phase III Trial," will take place on September 7, 2025, from 5:25 PM to 5:45 PM local time as part of a session on advances in targeted drug delivery [1].The company's proprietary PLEX technology enables controlled, prolonged drug release, and PolyPid plans to submit a New Drug Application (NDA) for its lead product candidate, D-PLEX₁₀₀, which aims to prevent surgical site infections after colorectal surgeries, expected in early 2026. The company also has a pipeline focused on oncology, obesity, and diabetes [1].
PolyPid's presentation at the ICRS Conference showcases the company's commitment to innovation in drug delivery and its progress in advancing surgical outcomes. The presentation will detail the successful Phase III trial of D-PLEX₁₀₀, highlighting the company's momentum towards potential regulatory approval [1].
However, the submission of the NDA for D-PLEX₁₀₀ is not expected until early 2026, suggesting potential delays in bringing the product to market. Additionally, the focus on a single product candidate for surgical site infections may indicate a lack of diversification in the company's drug development pipeline, making it vulnerable to potential market or regulatory setbacks [1].
References:
[1] https://www.quiverquant.com/news/PolyPid+Ltd.+to+Present+at+Israel+Controlled+Release+Society+Conference+on+Advances+in+Drug+Delivery+Technology
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet